Atea Pharmaceuticals, Inc.

Filed a patent for "dosage regimens for treatment or prophylaxis of dengue infection" on Mon, October 10, 2022

Filed a patent for "dosage regimens for treatment or prophylaxis of dengue infection" on Tue, November 22, 2022

Filed a patent for "beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment" on Thu, January 4, 2024

Filed a patent for "nucleotide hemi-sulfate salt for the treatment of hepatitis c virus" on Thu, January 18, 2024

Filed a patent for "advantageous morphic form of at-527 hemi-sulfate salt" on Thu, November 16, 2023